Reassessing the Benefits and Harms of Risk-Reducing Medication Considering the Persistent Risk of Breast Cancer Mortality in Estrogen Receptor-Positive Breast Cancer.
Jinani JayasekeraAmy ZhaoClyde B SchechterKathryn P LowryJennifer M YehMarc D SchwartzSuzanne C O'NeillKaren J WernliNatasha K StoutJeanne S MandelblattAllison W KurianClaudine IsaacsPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
The addition of risk-reducing medication to screening could further decrease the risk of breast cancer death. Clinical guidelines for high-risk women should consider integrating shared decision making for risk-reducing medication and screening on the basis of individual risk factors.